LifeMD, Inc.
- Open
- 3.09
- Day high
- 3.15
- Day low
- 3.06
- Prev close
- 3.09
- Volume
- 190K
- Mkt cap
- $152M
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 19.0
- P/S
- 0.7
- Yield
- —
- Per share
- —
LifeMD, Inc. (LFMD) is a Healthcare company listed on NASDAQ. The stock is down 50% over the past year. Drillr has 1 published research article covering LFMD.
LifeMD, Inc. (LFMD) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 3 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
LFMD earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Aug 5, 2026 | $-0.15 | $-0.16 | -9.8% | $47M | -3.8% |
| May 6, 2026 | $-0.14 | $-0.20 | -42.9% | $50M | +2.7% |
| Mar 9, 2026 | $-0.07 | $-0.04 | +39.1% | $6M | -87.9% |
| Nov 17, 2025 | $-0.06 | $-0.10 | -66.7% | $60M | +23.9% |
| Mar 10, 2025 | $-0.04 | $-0.02 | +50.0% | $64M | +7.8% |
| Nov 7, 2024 | $-0.10 | $-0.14 | -40.0% | $40M | -30.2% |
| Mar 11, 2024 | $-0.14 | $-0.12 | +14.3% | $45M | +10.8% |
| May 12, 2023 | $-0.16 | $-0.15 | +6.3% | $33M | +6.4% |
| Mar 22, 2023 | $-0.18 | $0.02 | +111.1% | $28M | -16.3% |
| Nov 10, 2022 | $-0.27 | $-0.03 | +88.9% | $31M | -1.4% |
| Aug 11, 2022 | $-0.23 | $-0.22 | +4.3% | $30M | -2.7% |
| May 13, 2022 | $-0.26 | $-0.25 | +3.8% | $29M | -7.9% |
LFMD insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 18, 2026 | LAROVERE JOANdirector | Grant | 35,000 | — |
| Aug 18, 2026 | Strawn John R Jrdirector | Grant | 50,000 | — |
| Aug 18, 2026 | Strawn John R Jrdirector | Grant | 35,000 | — |
| Aug 13, 2026 | Simon Robertodirector | Grant | 50,000 | — |
| Aug 13, 2026 | DiTrolio Josephdirector | Grant | 35,000 | — |
| Aug 13, 2026 | Simon Robertodirector | Grant | 35,000 | — |
| Aug 13, 2026 | Simon Robertodirector | Grant | 24,648 | — |
| Aug 13, 2026 | Simon Robertodirector | Grant | 6,162 | — |
| Aug 13, 2026 | MACRAE CALUM ARCHIBALDdirector | Grant | 35,000 | — |
| Jun 3, 2026 | Sripad Umeshofficer: Chief Technology Officer | Grant | 75,000 | — |
| May 13, 2026 | Kavthekar Atulofficer: Chief Financial Officer | Grant | 337,500 | — |
| Apr 1, 2026 | Pisano Christopher Aofficer: Chief Marketing Officer | Grant | 200,000 | — |
| Dec 11, 2025 | FRIEDEMAN JESSICAofficer: Chief Marketing Officer | Sell | 15,000 | $3.61 |
| Oct 8, 2025 | Strawn John R Jrdirector | Grant | 22,365 | — |
| Oct 8, 2025 | LAROVERE JOANdirector | Grant | 22,365 | — |
Source: LFMD SEC Form 4 filings, latest Aug 18, 2026. For informational purposes only — not investment advice.
See the full LFMD insider & 13F page →LifeMD, Inc. company profile
Overview
LifeMD, Inc. (NASDAQ:LFMD) is a direct-to-patient telehealth company founded in 1994 and headquartered in New York, New York. Originally known as Conversion Labs, Inc., the company rebranded to LifeMD in February 2021 to better reflect its evolution into a comprehensive virtual healthcare provider. The company has transformed from its early roots into a multi-brand telehealth platform that connects consumers directly to licensed healthcare professionals across various medical specialties. LifeMD went public in 2008 and has since expanded its offerings to include specialized telehealth brands, prescription medications, and digital health solutions, positioning itself as a leader in the rapidly growing direct-to-consumer healthcare market.
Business
LifeMD operates in the telehealth industry, which involves delivering healthcare services remotely through digital platforms and telecommunications technology. The company provides virtual medical consultations, prescription medications, and health-related products directly to consumers without requiring traditional in-person doctor visits. The company operates through multiple specialized telehealth brands, each targeting specific health conditions and demographics: 1. ShapiroMD focuses on hair loss treatment for both men and women, offering virtual consultations, prescription medications, patented over-the-counter products, and FDA-approved medical devices. This platform also provides female-specific topical compounded medications for hair restoration. 2. RexMD serves as the company's men's health brand, providing virtual medical treatment for various men's health needs including sexual health and hormone replacement therapy. This segment has grown to generate over $80 million in annualized revenue. 3. LifeMD Primary Care represents the company's flagship virtual primary care platform, offering subscription-based personalized healthcare that includes primary care, urgent care, and chronic disease management. The platform incorporates virtual consultations, prescription medications, diagnostics, and imaging services through a mobile-first approach. 4. Cleared specializes in allergy, asthma, and immunology treatments, providing personalized telehealth solutions for patients with respiratory and allergic conditions. 5. Nava MD targets female-oriented dermatology and skincare needs, offering virtual consultations with dermatologists and other specialized providers. The company's weight management program has become a significant growth driver, serving over 75,000 active patients by the end of 2024. This program focuses on GLP-1 medications (such as semaglutide and tirzepatide) for weight loss, combined with comprehensive lifestyle support including nutrition consultations and wellness coaching. Additionally, LifeMD operates WorkSimpli (formerly PDFSimpli), a software-as-a-service platform that allows users to create, edit, convert, sign, and share PDF documents. This business segment, while unrelated to healthcare, generates over $1 million in monthly EBITDA and serves approximately 158,000 active subscribers. Based on recent revenue figures, the telehealth business represents approximately 80% of total revenues, while WorkSimpli contributes roughly 20% of consolidated revenues.
Revenue model
LifeMD generates revenue through multiple business models across its telehealth and software platforms. The primary revenue streams include subscription-based services, where patients pay monthly fees for ongoing access to virtual care platforms and prescription medications. For example, the weight management program charges patients for continuous access to GLP-1 medications and related medical supervision. The company also operates on a direct-pay model where patients pay out-of-pocket for consultations and treatments, though this is increasingly supplemented by insurance reimbursements. LifeMD has been expanding its acceptance of commercial insurance and is preparing to launch Medicare coverage across multiple states, which should significantly reduce patient costs and expand the addressable market. Product sales constitute another revenue stream, particularly through the sale of over-the-counter products, FDA-approved medical devices, and prescription medications dispensed through the company's 50-state licensed pharmacy. The WorkSimpli segment operates on a software subscription model, charging users monthly or annual fees for PDF editing and document management services. The company's paying customers include individual consumers seeking convenient healthcare access, particularly those in underserved areas or those preferring virtual care over traditional in-person visits. The demographic spans various age groups, with particular strength in men's health (RexMD), weight management patients, and individuals seeking specialized care for conditions like hair loss and dermatology issues. Several factors influence LifeMD's margins and profitability. Positive margin drivers include the scalable nature of virtual consultations, which have low marginal costs once the platform infrastructure is established, and the company's vertically integrated pharmacy operations that capture additional value in the medication supply chain. The high gross margins (consistently above 85%) reflect the asset-light nature of telehealth services. Margin pressures come from customer acquisition costs, which can be significant in the competitive digital health marketing environment, and the need for continuous technology investment to maintain platform capabilities. Regulatory changes affecting telehealth reimbursement rates, competition from traditional healthcare providers entering the virtual space, and potential restrictions on compounded medications (particularly for weight loss treatments) could also impact margins. Additionally, the company's expansion into insurance-covered services, while expanding the market, may result in lower per-patient revenue compared to cash-pay models.
Competitive moat
LifeMD's competitive moat appears moderate but developing, with several defensive characteristics that provide some protection against competition. The company has built specialized brand recognition in specific therapeutic areas, particularly through RexMD for men's health and its weight management programs, which have established patient loyalty and trust in sensitive health categories. The company's integrated platform approach creates some switching costs for patients, as LifeMD combines virtual consultations, prescription fulfillment through its 50-state pharmacy, and ongoing care management in a single ecosystem. This vertical integration, particularly the pharmacy operations, provides operational control and additional revenue capture that pure-play telehealth platforms lack. Regulatory compliance and licensing across multiple states creates barriers to entry, as new competitors must navigate complex healthcare regulations, obtain appropriate licenses, and build relationships with licensed healthcare providers. LifeMD's established network of healthcare professionals and state-by-state licensing represents accumulated institutional knowledge and operational capability. However, the moat faces significant challenges. The telehealth industry has low inherent barriers to entry from a technology perspective, and large technology companies, traditional healthcare systems, and well-funded startups continue to enter the market. Companies like Amazon (with its healthcare initiatives), CVS Health, and Teladoc represent formidable competition with substantially greater resources. The company's reliance on digital marketing for customer acquisition makes it vulnerable to changes in advertising costs and platform policies. Additionally, regulatory changes could significantly impact the business model, particularly regarding prescription practices for controlled substances or changes to telehealth reimbursement policies. The competitive landscape suggests that LifeMD's moat is primarily based on execution, brand building in specific niches, and operational efficiency rather than fundamental structural advantages. Success will likely depend on the company's ability to maintain growth while building deeper patient relationships and expanding into insurance-covered services faster than competitors.
Risks & safety
LifeMD presents a moderate margin of safety with improving financial metrics but some structural concerns. **Cash and Liquidity Position:** - Cash and short-term investments: $34.4 million as of Q1 2025 - Current ratio: 0.82, indicating current liabilities exceed current assets - Quick ratio: 0.77, showing adequate liquid asset coverage - Positive operating cash flow: $3.1 million in Q1 2025, with $17.5 million for full year 2024 **Debt and Solvency:** - The company appears to have minimal traditional debt based on the negative debt-to-equity ratios - Total liabilities ($74.0 million) slightly exceed total assets ($73.6 million), creating a small equity deficit - However, the company has achieved positive GAAP net income in Q1 2025 and is generating positive EBITDA **Valuation Metrics:** - P/E ratio: 42.4x based on recent profitable quarter - EV/EBITDA: 10.8x, reasonable for a growing telehealth company - Price-to-book ratio indicates the stock trades above tangible book value **Other Considerations:** - Recent profitability achievement and strong revenue growth (49% year-over-year) provide operational momentum - Raised 2025 revenue guidance to $268-275 million with projected EBITDA of $31-33 million - Working capital deficit requires careful cash flow management but improving operational performance should address this concern
Recent development
Over the past several years, LifeMD has undergone significant strategic transformation, evolving from a struggling digital marketing company into a profitable telehealth platform. The most significant pivot occurred with the launch and rapid scaling of the weight management program, which grew from zero patients in early 2023 to over 75,000 active patients by the end of 2024. This program focuses on GLP-1 medications for weight loss and has become a major revenue driver. The company has pursued vertical integration by establishing its own 50-state licensed pharmacy, which provides operational control over prescription fulfillment and captures additional value in the medication supply chain. This pharmacy infrastructure supports all of LifeMD's telehealth brands and enables more efficient patient care coordination. Strategic partnerships have become increasingly important, with notable collaborations including partnerships with LillyDirect and NovoCare for GLP-1 medication access, and a significant relationship with Medifast that included $10 million in collaboration fees and $10 million in equity investment. These partnerships help expand patient access to branded medications and reduce reliance on compounded alternatives. The company has been expanding insurance acceptance as a key strategic initiative, moving away from a purely cash-pay model. LifeMD began accepting commercial insurance and is preparing to launch Medicare coverage across 26 states initially, targeting 49 states by Q2 2025. This expansion is expected to significantly reduce patient costs and expand the total addressable market. Brand diversification and expansion continues with the acquisition of Optimal Human Health MD to enter women's health markets, the launch of men's hormone replacement therapy under the RexMD brand, and preparations to enter behavioral health services. The company is also developing a LifeMDPlus membership program to enhance patient engagement and retention. Technology improvements include the implementation of AI-driven patient communication systems and workflow optimization tools to improve operational efficiency and patient experience. These technological enhancements support the company's goal of providing personalized, scalable healthcare services.
LFMD company profile · for informational purposes only — not investment advice.
Track LFMD with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free